An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
A phase 2 trial of Acalabrutinib in mantle cell lymphoma, run by Acerta Pharma BV, active and no longer recruiting.
Overview
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT02213926 by Acerta Pharma BV, with 124 participants enrolled, started 2015-03-02 and due to reach its primary completion in 2020-12-04. Interventions recorded: ACP-196 (acalabrutinib). Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malign
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialA Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Shares Acalabrutinib, Mantle cell lymphoma, AstraZeneca.
- TrialACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Shares Acalabrutinib, AstraZeneca.
- TrialA Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
Shares Acalabrutinib, AstraZeneca.
- TrialAn Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
Shares Acalabrutinib, AstraZeneca.
- TrialStudy of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Shares Acalabrutinib, AstraZeneca.